Background: Chronic lung infection with Pseudomonas aeruginosa is the main cause
| INTRODUCTION
Chronic lung infection with Pseudomonas aeruginosa is associated with bronchopulmonary inflammation, tissue damage, bronchiectasis, and progressive declining lung function, and is the main cause of premature death or lung transplantation in patients with cystic fibrosis (CF). 1 Intermittent lung colonization precedes chronic infection, 2 and preventing or postponing chronicity is of paramount importance in CF treatment. 3 Important indicators for chronic lung infection include increasing levels of Immunoglobulin G (IgG) antibodies against P.
aeruginosa in serum 2 to 3 years before the lung infections becomes chronic and growth of mucoid P. aeruginosa strains in sputum. 4 Respiratory infection with P. aeruginosa causes increases of antibodies against P. aeruginosa both systemically 5 and locally in saliva, tears, and nasal secretions. 6 Secretory immunoglobulin A (s-IgA) is the predominating antibody on mucosal surfaces. 6, 7 In the initial stages of lung colonization, P. aeruginosa can usually be eradicated. However, patients are usually re-colonized with the same clone from the patients' own sinuses; thus, the sinuses can function as a sustainable bacterial reservoir. [8] [9] [10] In many cases, colonization of paranasal sinuses may precede intermittent lung colonization.
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This encourages efficient treatments of sinuses that may subsequently spare colonization of the lower airways. Unfortunately, no non-invasive method can currently detect P. aeruginosa sinusitis with a high specificity or sensitivity. Possible methods include nasal lavage 9 or swabs from the middle meatus; however, in our experience (unpublished), there is a risk of false negative results, because the pathogenic bacteria can be present in, for example, the frontal or sphenoid sinuses. In a diseased sinus with mucosal oedema, nasal lavage may not enter these cavities, encouraging research in other modalities.
However, the way of drainage from any paranasal sinus is through its ostium. Therefore, secretions may not be ultimately hidden from sampling, but they will appear in descending airways at some time.
Our research group has shown that when P. aeruginosa colonizes the sinuses, elevated secretory (s) -IgA levels can be detected in nasal mucosa and saliva. Further, values are significantly higher in patients' lung colonized with P. aeruginosa or other GNB. 6 Therefore, we hypothesized that increasing levels of s-IgA in saliva against P. aeruginosa standard antigen (St-Ag) precede intermittent P. aeruginosa lung colonization.
In this prospective study, saliva samples were collected and analyzed in order to test if P. aeruginosa or GNB lung colonization could be predicted. If so, we provide a diagnostic antibody assay for early detection of P. aeruginosa sinus colonization, and an eradication attempt could be initiated. In this way, the lungs may be spared from colonization, inflammation, and irreversible lung damage. Eradication regimens include endoscopic sinus surgery (ESS) with adjuvant therapy including systemic antibiotics, nasal irrigation with saline and antibiotics, 12, 13 or nasal inhalation of antibiotics. 14 
| MATERIAL AND METHODS

| Patients
The CF diagnosis was based on characteristic clinical features, abnormal sweat electrolytes, and genotypes. All CF patients from the Copenhagen CF Centre are followed in the out-patient clinic every month. A clinical exam is followed by routine microbiological surveillance of sputum samples or samples obtained by endolaryngeal suction. Lower airway origin of the samples is verified by microscopy.
Further, regularly blood samples are taken and analyzed for anti-bacterial antibodies, as described previously. 6, 15 All patients diagnosed with CF and free from GNB lung infection and colonization followed at the Copenhagen CF Centre from November 1, 2013 to June 1, 2015, were eligible for the study.
| Lung infection status
We divided patients into 4 groups according to the bacterial flora 6,15 :
1. Chronically infected with P. aeruginosa (CF + P (c)) was defined as presence of this bacterium in 6 consecutive monthly samples or a shorter period if there were 2 or more precipitating antibodies in serum.
intermittent or chronic infection status, using a generalized linear mixed-effect logistic regression model. The data span 2 periods, so some patients are available and contribute to 2 sets of before-after status changes which is why we included a random intercept of subject to account for repeated measurements on some patients. Because of the small number of events, ie, individuals changing status, we were only able to include a single predictor at a time.
The number of observations and events were limited in the dataset, so the logistic regression model could only accommodate a single predictor before running into problems with complete separation. Consequently, we first examined if there was any effect of period, because the 2 periods span different lengths, but no difference was found. We examined each of the 2 predictors independently using a logistic regression model with an initial model that included a (log)
linear effect of the predictor as well as the predictor squared to allow for a nonlinear relationship between the log odds of changing status and the predictor. However, allowing for nonlinearity did not contribute anything statistically significant to the model for any of the predictors, and, therefore, we report the results from the logistic regression model.
Data were analysed using SAS (SAS Institute Inc., version 9.4, NC, USA).
| Ethics
The study was approved by the local ethics committee (H-1-2013-032). Informed consent was obtained from all patients. Parental consent was obtained for patients <18 years of age. Obtaining the saliva samples did not cause any discomfort. This study was carried out in accordance with the principles of the Helsinki Declaration.
| RESULTS
Forty-nine CF patients (28/21 female/male, median age 15 years, range 5-45 years) free from lung colonization with P. aeruginosa (CF-P) or other GNB, were included in this prospective study. Thirtytwo patients were dF508 homozygous, 15 were dF508 heterozygous, and 2 had other mutations.
A total of 110 measurements of s-IgA in saliva against St-Ag and IgG in serum against St-Ag were analyzed from 49 CF patients. To increase power, 21 measurements (from 21 patients) obtained in our prospective study in 2009 6 were included in these 110 measurements.
We only included measurements on patients who had already agreed to participate in the present study. During a median of 8.5 months follow-up (range 6-66 months), 25 patients changed their infection status. Seven patients changed from free of lung colonization to intermittent lung colonization, 9 changed to chronic lung infection, and 9
patients changed to lung colonization or infection with other GNB (Figure 1 ).
| s-IgA
Mean s-IgA was higher in patients who changed lung infection status compared with patients who remained free from lung colonization:
the mean OD was 0.50 and 0.33, respectively (Table 1) . The model is plotted in Figure 2 and includes a prediction band where 95% of new measurements are predicted to fall within. The model, however, failed to reach statistical significance, as the probability was calculated to be P = 0.056, 1-tailed, using a likelihood-ratio test.
| IgG
Mean serum IgG was higher in patients who changed their lung infection status compared with patients who remained free from lung colonization ( Table 2) . However, the model was inferior compared with the one with s-IgA, with regard to detecting a change (P = 0.16, 1-tailed), using a likelihood-ratio test.
| DISCUSSION
We have previously reported that patients' lung colonized with P.
aeruginosa or other GNB have higher levels of s-IgA against P.
aeruginosa St-Ag in saliva than patients free of lung colonization. 6 This may result from a local mucosal antibody response to P. aeruginosa when it first colonizes the sinuses.
Sinus colonization often precedes intermittent lung colonization with P. aeruginosa, 11 and intermittent colonization precedes chronic lung infection.
2 FIGURE 1 Change in lung infection status. Forty-nine CF patients free from GNB lung colonization were included in this prospective study. Repeated saliva samples were obtained from each of the patients with at least a 6-month interval. However, 21 samples from our prospective study in 2009 6 were also included, to increase power.
Consequently, 110 measurements from 49 patients were included. In the 49 patients, we observed 61 events where patients could change in lung infection status. The numbers in Table 1 refer to these events. During a median of 8.5-months follow-up, 7 patients changed to intermittent lung colonization with P. aeruginosa (Pa + (i)), 9 patients changed to chronic lung infection with P. aeruginosa (Pa + (c)) and 9 patients changes status to lung colonization with other gram-negative bacteria (GNB+)
Most interestingly, our data provides preliminary evidence that our saliva s-IgA model may predict an early worsening in lung infection status, presumably acting as a surrogate marker of P. aeruginosa or other GNB mediated bacterial sinusitis and, thereby, identifying patients at risk of subsequent lung colonization and infection with GNB. However, the model did not reach statistical significance probably due to limited power, and it must, therefore, be confirmed in larger prospective studies. Nevertheless, the results from this study are supported by a recent study by Mauch et al 17 who concluded that s-IgA measurement can be used as a screening model for patients at risk of chronic infection.
Measuring IgG levels in serum is a useful tool for identifying patients at risk of becoming chronically lung infected, 4 and we showed that the s-IgA model was superior to serum IgG in detecting early colonization. In this way, the 2 assays may very well supplement each other consecutively, and we recommend that specific antibodies in both saliva and serum should be measured regularly.
The reason why s-IgA is superior at early infections may be a result of the different action of the immune system in early versus late infections. When the sinuses are colonized by P. aeruginosa, the immune response is dominated by a high production of sIgA that binds to P. aeruginosa antigens and prevent complement activation and the recruitment of polymorphonuclear leucocytes, thereby, reducing the inflammatory and systemic response. 8, 18 Both ESS with adjuvant therapy 12, 13 and nasal inhalation of antibiotics 14 can eradicate sinus bacteria, highlighting the importance of timely intervention against a potential sinonasal bacterial reservoir.
Whether a given s-IgA value may be helpful to identify patients who should be offered a sinus eradication attempt even before intermittent lung colonization occurs, should be investigated in a clinical trial.
Both ESS 13 and administration of topical nasal antibiotics 19 are safe procedures in CF.
Our study has other limitations. The s-IgA model cannot reliably distinguish between lung colonization with P. aeruginosa or other GNB due to cross-reaction of antibodies against common antigens in these bacteria, unless absorption studies are carried out. 20 However, ESS has also proven successful in eradicating GNB other than P.
aeruginosa, 13 minimizing the importance of exact identification of the pathogen by serological methods. Nevertheless, there certainly are different strategies for how aggressively to treat different GNB.
Another limitation of this study is the usage of s-IgA measurements from our previous published paper. 6 Pending on better modalities for detecting upper airway P.
aeruginosa colonization, we believe that s-IgA saliva measurements may be a helpful clinical tool. Obtaining saliva samples is very easy and without any discomfort to the patients including children, and the IgG assay is commercially available and can easily be modified for detection of sIgA.
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